Publications by authors named "F Patriarca"
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study.
Br J Haematol
December 2024
Brexucabtagene autoleucel (brexu-cel) has revolutionized the treatment of patients affected by mantle cell lymphomas. In this prospective, observational multicentre study, we evaluated 106 patients, with longitudinal brexu-cel kinetics in peripheral blood monitored in 61 of them. Clinical outcomes and toxicities are consistent with previous real-world evidence studies.
View Article and Find Full Text PDFIntroduction: MGRS are new rare clinical entities, whose recognition and optimal management is evolving.
Methods: To implement real-life data, we retrospectively analysed a multicentre cohort of 60 patients with renal biopsy-proven MGRS receiving mainly novel treatments (between 2006 and 2021) in eight Italian centres. Based on renal biopsy, patients were divided into two subgroups: AL amyloidosis (70%, n = 42) and other-MGRS (30%, n = 18).
Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation.
Transplant Cell Ther
November 2024
Article Synopsis
- Allogeneic stem cell transplantation (allo-SCT) offers curative potential for multiple myeloma patients but is effective in only a minority, with some patients experiencing long-term survival after relapse thanks to a combination of antimyeloma drugs and donor T cells.
- A study evaluating 242 multiple myeloma patients who underwent allo-SCT revealed a median overall survival of 39.4 months and highlighted factors like older age and previous therapies that predict shorter survival outcomes.
- Among 118 relapsed patients, various treatments were employed, with a significant portion receiving multiple lines of salvage therapy, including chemotherapy and immunomodulating agents, demonstrating a diverse treatment approach post-relapse.
Purpose: Despite the importance of adherence to immunosuppressants (IMMs) after an allogeneic haematopoietic stem cell transplant (HSCT) for the treatment of acute graft-versus-host disease (aGvHD), no studies to date have reported the experiences of such patients concerning medication adherence (MA). Therefore, the aim of the study was to explore the perspective on MA to immunosuppressive oral therapy among allogeneic HSCT patients with aGvHD.
Methods: A qualitative descriptive study following a reflexive thematic analysis methodological approach was performed involving a purposive sample of 16 patients with aGvHD who were being cared for in the outpatient setting of a bone marrow transplant centre and were willing to participate.